Valence ロゴ
人気
ログイン

ウォッチリストに追加
Proチャート

Tiziana Life Sciences Ltd

NasdaqCM: TLSA · リアルタイム株価 · USD
1.15
+0.01 (0.88%)
終値時点： Aug 17, 2026, 3:59 PM
1.13
-1.74%
時間外: 5:07 PM

Tiziana Life Sciences Ltd (TLSA) Stock Price, Analysis & Data

0.88%
買気配1.13
時価総額146.35M
売上高（TTM）n/a
純利益（TTM）-18.43M
ベータ0.46
EPS（TTM）-0.16
PER（TTM）n/a
予想PER-5.76
PBR（TTM）14.94
PSR（TTM）n/a
Earnings Daten/a
売気配1.11
出来高1,912,049
平均出来高（20日）428,162
始値1.15
前日終値1.14
当日レンジ1.06 - 1.17
52週レンジ0.87 - 2.35
アナリストn/a
目標株価9.07 (688.70%)
配当n/a
権利落ち日n/a

TLSAについて

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Nov 20, 2018
従業員数 10
上場取引所 NasdaqCM
ティッカー TLSA
ウェブサイト https://www.tizianalifesciences.com
企業情報の全文

業績

2025年のTiziana Life Sciences Ltdの売上高は0で、前年の0からundefined%の増加でした。 利益は-18.43Mで、55.37%の増加でした。

財務諸表

アナリスト予想

1件のアナリスト評価によると、TLSA株の平均レーティングは「null」です。12か月後の目標株価は9.07で、直近株価から688.7%の上昇余地となります。

株価予想

決算サプライズ

Tiziana Life Sciences LtdはDec 27, 2022に四半期決算を発表しました：
  • 売上高は n/a で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -0.06 で、予想を下回りました , うち -Infinity% の前年比減少.
    news image

    2週間前 · Proactive

    Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo...

    news image

    1か月前 · Proactive

    Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul...

    news image

    2か月前 · Motley Fool

    Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

    Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

    news image

    2か月前 · Proactive

    Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a...

    news image

    2か月前 · Proactive

    Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress...

    2ページ中1ページ